As Zy Therapeutics prepares for the 2025 American Epilepsy Society (AES) Annual Meeting, the company is placing a strong emphasis on building the strategic relationships needed to advance its rare-epilepsy programs.
AES 2025 will serve as a key forum for connecting with clinicians, advocacy organizations, researchers, CRO partners, and potential co-development collaborators. With pivotal program planning now underway, these conversations are essential for accelerating clinical execution and expanding access to expertise across the rare-disease ecosystem.
Throughout the meeting, members of the Zy Therapeutics leadership team will participate in scheduled one-on-one discussions focused on:
- Trial site selection and investigator engagement
- Opportunities for natural history data collection
- Real-world insights from SWS specialists
- Partnerships supporting commercial and medical-affairs readiness
By fostering these partnerships, Zy Therapeutics continues to strengthen the foundation needed to bring innovative therapies to individuals affected by rare and severe epilepsies.
